Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes

Abstract

This cohort study assesses the association between plasma total tau level and later development of dementia by comparing laboratory, clinical, and autopsy data from participants in the Framingham Heart Study in the United States and the Memento Study in France. Can plasma total tau be used as a biomarker for dementia and related endophenotypes? In this cohort study of samples from 1453 participants in the Framingham Heart Study and 367 individuals in the Memento study, plasma total tau was associated with endophenotypes of dementia and with the risk of incident clinical Alzheimer disease dementia. Measuring plasma total tau may help with risk stratification and subsequent enrollment of high-risk individuals in dementia prevention trials. Blood-based biomarkers have the potential to improve the identification of persons with the greatest dementia risk for inclusion in dementia prevention trials through low-cost and minimally invasive screening. To investigate the use of plasma total tau as a blood biomarker for dementia and related endophenotypes. This prospective cohort study used data from the US community-based Framingham Heart Study with replication in the Memento study, a multicenter cohort of persons with mild cognitive impairment or subjective cognitive complaints recruited from memory clinics across France. Total tau levels were measured from stored plasma samples in Framingham Heart Study participants during 2004 to 2011. Dementia follow-up occurred across a median of 6 years (interquartile range, 5-8 years) for persons 65 years and older who were dementia free at baseline. Plasma and/or cerebrospinal fluid samples were obtained from Memento study participants from April 19, 2011, to June 22, 2016. Dementia follow-up took place over a median of 4 years (interquartile range, 3-5 years). Data analysis was performed from January to November 2018. Plasma total tau level measured using single-molecule array technology. Incidence of dementia of any cause (all dementia) and dementia due to clinical Alzheimer disease (AD dementia). Among the 1453 participants in the Framingham dementia study sample, the mean (SD) age was 75 (7) years; 792 (54.5%) were female. Among the 367 individuals in the replication cohort, the mean (SD) age was 69 (9) years; 217 (59.1%) were female. Of 134 cases of incident all dementia in the Framingham sample, 105 were AD dementia. After adjustment for age and sex, each SD unit increase in the log of plasma total tau level was associated with a 35% increase in AD dementia risk (hazard ratio [HR], 1.35; 95% CI, 1.10-1.67). The addition of plasma total tau to a model including age and sex improved the stratification of participants for risk of AD dementia (net reclassification improvement, 0.382; 95% CI, 0.030-0.716). Higher plasma total tau level was associated with poorer cognition across 7 cognitive tasks ( P  < .05) and smaller hippocampi (hippocampal volume: β [SE] = 0.002 [0.001]; P  = .003) as well as neurofibrillary tangles (β [SE] = 0.95 [0.45]; P  = .04) and microinfarcts (odds ratio, 3.04; 95% CI, 1.26-7.37) at autopsy. In the replication cohort, plasma total tau level weakly correlated with cerebrospinal fluid total tau level (Spearman correlation coefficient, 0.16; P  = .07), but plasma total tau was at least as strongly associated with incident AD dementia as cerebrospinal fluid total tau (log plasma total tau: HR, 2.33; 95% CI, 1.00-5.48; log cerebrospinal fluid total tau: HR, 2.14; 95% CI, 1.33-3.44) after adjustment for age and sex. The findings suggest that plasma total tau levels may improve the prediction of future dementia, are associated with dementia endophenotypes, and may be used as a biomarker for risk stratification in dementia prevention trials.